Abstract
Original language | English |
---|---|
Journal | European Pharmaceutical Review |
Volume | 20 |
Issue number | 2 |
Pages (from-to) | 18-19 |
ISSN | 1360-8606 |
Publication status | Published - 2015 |
Bibliographical note
CBS Library does not have access to the materialCite this
}
Drug Pricing Reforms : The Danish Experience. / Kaiser, Ulrich; Mendez, Susan J.; Rønde, Thomas; Ullrich, Hannes.
In: European Pharmaceutical Review, Vol. 20, No. 2, 2015, p. 18-19.Research output: Contribution to journal › Journal article › Research › peer-review
TY - JOUR
T1 - Drug Pricing Reforms
T2 - The Danish Experience
AU - Kaiser, Ulrich
AU - Mendez, Susan J.
AU - Rønde, Thomas
AU - Ullrich, Hannes
N1 - CBS Library does not have access to the material
PY - 2015
Y1 - 2015
N2 - Reference price systems for prescription drugs have found widespread use as cost containment tools. Under such regulatory regimes, patients co-pay a fraction of the difference between pharmacy retail price of the drug and a reference price. Reference prices are either externally (based on drug prices in other countries) or internally (based on domestic drug prices) determined. In a recent study, we analysed the effects of a change from external to internal reference pricing in Denmark in 2005, finding that the reform led to substantial reductions in prices, producer revenues, and expenditures for patients and the health insurance system. We also estimated an increase in consumer welfare but the size effect depends on whether or not perceived quality differences between branded and other drugs are taken into account.
AB - Reference price systems for prescription drugs have found widespread use as cost containment tools. Under such regulatory regimes, patients co-pay a fraction of the difference between pharmacy retail price of the drug and a reference price. Reference prices are either externally (based on drug prices in other countries) or internally (based on domestic drug prices) determined. In a recent study, we analysed the effects of a change from external to internal reference pricing in Denmark in 2005, finding that the reform led to substantial reductions in prices, producer revenues, and expenditures for patients and the health insurance system. We also estimated an increase in consumer welfare but the size effect depends on whether or not perceived quality differences between branded and other drugs are taken into account.
M3 - Journal article
VL - 20
SP - 18
EP - 19
JO - European Pharmaceutical Review
JF - European Pharmaceutical Review
SN - 1360-8606
IS - 2
ER -